| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 07/03/2003 | US20030124690 Novel compounds |
| 07/03/2003 | US20030124678 Interleukin-2 mutants with reduced toxicity |
| 07/03/2003 | US20030124677 Amino-terminally truncated MCP-2 as chemokine antagonists |
| 07/03/2003 | US20030124655 Receptor protein specifically recognizing bacterial dna |
| 07/03/2003 | US20030124582 Polypeptide encoded by a polynucleotide of given sequence; detecting the effect of a test compound on the production of mRNA; use in identifying agonists/antagonists that may be useful in therapy |
| 07/03/2003 | US20030124567 Use of a leptospire protein preventing and/or diagnosing and/or treating animal or human leptospirosis |
| 07/03/2003 | US20030124550 Method of screening drug for hepatitis C |
| 07/03/2003 | US20030124517 Hepatitis A virus nucleotide sequences, recombinant proteins and uses thereof |
| 07/03/2003 | US20030124511 Method of production of purified hepatitis a virus particles and vaccine preparation |
| 07/03/2003 | US20030124193 Atomizing nozzles include a liquid nozzle adapted to disperse a supply of liquid and a gas nozzle adapted to disperse a supply of gas; spray drying at a commercial plant scale. |
| 07/03/2003 | US20030124150 Kit for reducing aching |
| 07/03/2003 | US20030124148 Method for producing autogenous vaccines for treating chlamydial infections in mammals and humans |
| 07/03/2003 | US20030124145 Avian polynucleotide vaccine formula |
| 07/03/2003 | US20030124142 Immunomodulatory constructs and their uses |
| 07/03/2003 | US20030124136 Immunotherapy for reversing immune suppression |
| 07/03/2003 | US20030124135 Recombinant intracellular pathogen vaccines and methods for use |
| 07/03/2003 | US20030124121 Treating septic arthritis |
| 07/03/2003 | US20030124111 Antimicrobial agent |
| 07/03/2003 | US20030124110 Use of modified lysozyme c to prepare medicinal compositions for the treatment of some serious diseases |
| 07/03/2003 | US20030124092 IL-17 like molecules and uses thereoflike molecules and uses thereof |
| 07/03/2003 | US20030124054 Antitumor agents; anticancer agents; viricides |
| 07/03/2003 | CA2473862A1 Pyridoquinoxaline antivirals |
| 07/03/2003 | CA2471136A1 Mono-and dual chemokine/cytokine constructs |
| 07/03/2003 | CA2471089A1 Pyridoquinoxaline antivirals |
| 07/03/2003 | CA2471081A1 Formulation & dosage form for the controlled delivery of therapeutic agents |
| 07/03/2003 | CA2470995A1 Methods of treating bacterial infections in dogs and cats |
| 07/03/2003 | CA2470964A1 Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors |
| 07/03/2003 | CA2470938A1 Treatment of ebv and khsv infection and associated abnormal cellular proliferation |
| 07/03/2003 | CA2470594A1 Leptin proteins |
| 07/03/2003 | CA2470063A1 Parmaceutical agents and methods for tissue and vascular regeneration |
| 07/03/2003 | CA2470055A1 Methods for wet granulating azithromycin |
| 07/03/2003 | CA2469918A1 Method for preparing echinocandin derivatives and their compositions |
| 07/03/2003 | CA2468882A1 A library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism |
| 07/03/2003 | CA2448811A1 Thiochromenones used to combat painful conditions and neurodegenerative diseases |
| 07/02/2003 | EP1323738A1 Negatively charged polysaccharide derivable form Aloe Vera |
| 07/02/2003 | EP1323730A1 Novel polypeptides and anti-hiv drugs containing the same |
| 07/02/2003 | EP1323726A1 Erythromycin derivatives and medicines containing the same |
| 07/02/2003 | EP1323428A2 Avirulent Salmonella typhi microbes and uses thereof |
| 07/02/2003 | EP1322769A2 Protein phosphatases |
| 07/02/2003 | EP1322763A2 Listeria inocua , genome and applications |
| 07/02/2003 | EP1322762A2 Haemophilus influenzae antigens and corresponding dna fragments |
| 07/02/2003 | EP1322761A1 A humanized antibody to surface antigen s of hepatitis b virus and a preparing method thereof |
| 07/02/2003 | EP1322760A2 G-protein coupled receptors |
| 07/02/2003 | EP1322755A1 Human and mouse targeting peptides identified by phage display |
| 07/02/2003 | EP1322673A1 Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative |
| 07/02/2003 | EP1322666A2 Hiv peptides from tat,rev and wef conserved regions and their application as e.gvacine compnents |
| 07/02/2003 | EP1322665A2 Hiv peptidesform concerved regions in gag p17 and 924 and their application in e.g vacines |
| 07/02/2003 | EP1322661A1 Triterpenes having fungicidal activity against yeast |
| 07/02/2003 | EP1322656A2 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 07/02/2003 | EP1322648A1 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents |
| 07/02/2003 | EP1322641A1 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases |
| 07/02/2003 | EP1322638A1 Antifungal and/or antiparasitic pharmaceutical composition and novel indole derivatives as active principle of such a composition |
| 07/02/2003 | EP1322636A1 Farnesyl transferase inhibiting 6- (substituted phenyl)methyl]-quinoline and quinazoline derivatives |
| 07/02/2003 | EP1322631A2 Methods of providing and using compounds ( retinoids ) having activity as inhibitors of cytochrome p450rai |
| 07/02/2003 | EP1322623A2 Hydroxy acid integrin antagonists |
| 07/02/2003 | EP1322616A2 Quinoline-(c=o)-(di-, tri- and tetrapeptide) derivatives as caspase inhibitors |
| 07/02/2003 | EP1322613A1 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases |
| 07/02/2003 | EP1322611A1 Chemical compounds |
| 07/02/2003 | EP1322599A2 Hiv integrase inhibitors |
| 07/02/2003 | EP1322336A1 Method of increasing testosterone and related steroid concentrations in women |
| 07/02/2003 | EP1322332A2 Compositions and methods for inhibition of hiv-1 infection |
| 07/02/2003 | EP1322331A2 Fatty acid synthase inhibitors |
| 07/02/2003 | EP1322329A1 Split enveloped virus preparation |
| 07/02/2003 | EP1322328A2 Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| 07/02/2003 | EP1322327A1 Stabilisation of plasmid inheritance in bacteria by preventing multimerisation |
| 07/02/2003 | EP1322325A1 Inhibiting hepatitis c virus processing and replication |
| 07/02/2003 | EP1322321A2 Use of lipopeptides or lipoproteins for treating lung infections and lung tumours |
| 07/02/2003 | EP1322319A1 Use of il-8 protein modulators in the treatment of viral infections |
| 07/02/2003 | EP1322317A1 Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins |
| 07/02/2003 | EP1322316A1 Diuretic or sulphonylurea for use in antiviral treatment |
| 07/02/2003 | EP1322309A2 High affinity small molecule c5a receptor modulators |
| 07/02/2003 | EP1322307A1 Methods for treating cell proliferative disorders and viral infections |
| 07/02/2003 | EP1322300A1 Inhalation particles incorporating a combination of two or more active ingredients |
| 07/02/2003 | EP1322292A2 Microparticle compositions and methods for the manufacture thereof |
| 07/02/2003 | EP1322291A1 Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight |
| 07/02/2003 | EP1322290A1 Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight |
| 07/02/2003 | EP1322288A1 Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions |
| 07/02/2003 | EP1322287A2 Microparticles for delivery of the heterologous nucleic acids |
| 07/02/2003 | EP1322162A1 Disinfectant agent |
| 07/02/2003 | EP1322156A1 Disinfectant |
| 07/02/2003 | EP1224180B1 Substituted azoles |
| 07/02/2003 | EP1175429B1 Halo derivatives of 9-deoxo-9a-aza-9a-homerythromycin a |
| 07/02/2003 | EP1150666A4 Stimulating neutrophil function to treat inflammatory bowel disease |
| 07/02/2003 | EP1045849B1 Purine derivatives having phosphodiesterase iv inhibition activity |
| 07/02/2003 | EP0973780B1 Antibacterial substituted 7-acylamino -3-(methylhydrazono) methyl-cephalosporins and intermediates |
| 07/02/2003 | EP0973779B1 Crystalline amine salt of cefdinir |
| 07/02/2003 | EP0923292B1 Improved method for systemic administration of 2,4-dienoic acid-type insecticides to terrestrial mammals |
| 07/02/2003 | EP0879282B1 Immunotherapy using cytotoxic t lymphocytes (ctl) |
| 07/02/2003 | EP0826043B1 Methods for modulating t cell survival by modulating bcl-xl protein level |
| 07/02/2003 | CN1427892A Virulence genes, proteins and their use |
| 07/02/2003 | CN1427889A Hybrid cells obtainable from antigen presenting cells |
| 07/02/2003 | CN1427846A Uridine derivatives as antibiotics |
| 07/02/2003 | CN1427844A Bis-(N,N'-bis-(2-haloethyl) amino) phosphoramidates as antitumor agents |
| 07/02/2003 | CN1427839A Charged compounds comprising nucleic acid binding moiety and uses therefor |
| 07/02/2003 | CN1427827A 2-Hydroxy-mutilin carbamate derivatives for antibacterial use |
| 07/02/2003 | CN1427826A Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl IV, processes for their preparation, and their use |
| 07/02/2003 | CN1427725A Casein derived peptides and uses thereof in therapy |
| 07/02/2003 | CN1427723A Composition for treatment of B-type hepatitis and liver cirrhosis |
| 07/02/2003 | CN1427722A Method for treatment or prevention of flavivirus infections using nucleoside analogues |
| 07/02/2003 | CN1427721A Peptide deformylase inhibitors |